Beta 2 agonists and the incidence of Parkinson’s disease.
|アブストラクト||A recent study found a decreased risk of Parkinson's disease (PD) associated with the beta2 agonist salbutamol. However, other mechanisms may explain this apparent association. Using the United Kingdom Clinical Practice Research Datalink, we formed a cohort of 2,430,884 patients aged 50 or over between 1995 and 2016. During follow-up, 8,604 cases of PD were identified and matched to 86,040 controls on sex, age, date of cohort entry, and duration of follow-up, after applying a one-year latency time window. Incidence rate ratios (RRs) of PD associated with use of beta2 agonists were estimated using conditional logistic regression. Ever use of beta2 agonists was associated with a 17% decreased rate of PD (RR 0.83; 95% CI 0.75-0.91) compared with no use. However, this association was limited to early short-term use, and was no longer observed after more than 2 years of cumulative duration of use (RR 0.97; 95% CI 0.80-1.17). A similar pattern was observed when stratifying by time since first beta2 agonist prescription and by duration of follow-up. The apparent association of beta2 agonists with a decreased risk of PD is likely the result of reverse causality rather than a biological effect of these drugs on the risk of PD.|
|ジャーナル名||American journal of epidemiology|
|投稿者||Giorgianni, Francesco; Ernst, Pierre; Dell'Aniello, Sophie; Suissa, Samy; Renoux, Christel|
|組織名||Center for Clinical Epidemiology, Lady Davis Research Institute, Jewish General;Hospital, McGill University, Montreal, Quebec, Canada.;Department of Epidemiology, Biostatistics, and Occupational Health, McGill;University, Montreal, Quebec, Canada.;Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec,;Canada.|